Read by QxMD icon Read


Xiaolong Jiao, Sonia Pulgar, Marley Boyd, Fadi Braiteh, Beloo Mirakhur, Susan Pitman Lowenthal, Patricia Fox, Jennifer Frytak, David Cox, A Scott Paulson
OBJECTIVE: This study was conducted to understand treatment patterns and clinical outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients treated in a large community oncology network. METHODS: This retrospective study used the McKesson Specialty Health/US Oncology Network iKnowMed electronic health record database with supplemental chart review. Eligibility criteria included a metastatic neuroendocrine tumor diagnosis between January 1, 2008, and to December 31, 2012; at least 2 US Oncology Network visits; and age at least 18 years...
February 2018: Pancreas
Jesse Peterson, Holly Budlong, Tim Affeldt, Kyle Skiermont, Gregg Kyllo, Al Heaton
Biosimilars have the potential to greatly reduce medication costs in the United States. As of July 1, 2017, 5 biosimilars have been approved by the FDA, but only 2 are available for purchase. This commentary outlines the efforts of an integrated health system to ensure biosimilar accessibility and discusses the current challenges and future implications. We highlight the implementation of a health plan policy and how a health system's formulary committee can encourage use while considering provider perceptions and operational challenges...
December 2017: Journal of Managed Care & Specialty Pharmacy
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Anesthesiology
George S Bause
Laughing-gas showman G.Q. Colton franchised dental extraction under 100% nitrous oxide in many large American cities before popularizing the practice with French Imperial Court dentist T.W. Evans in France and then England. Chicago dentist Z. Rogers helped surgeon E. Andrews oxygenate nitrous oxide, with neither man changing significantly the clinical practices of others. London's F.W. Hewitt and Pittsburgh's S.J. Hayes oxygenated anesthetics with greater clinical impact. By 1920, E.I. McKesson had publicized his practice of secondary saturation with bursts of 100% nitrous oxide to relax musculature in anesthetized patients...
January 2017: Journal of Anesthesia History
Nicholas J Robert, Hans-Peter Goertz, Pooja Chopra, Xiaolong Jiao, Bongin Yoo, Debra Patt, Vincent Antao
BACKGROUND: Pertuzumab (Perjeta(®)), a HER2/neu receptor antagonist, was approved by the US Food and Drug Administration in June 2012 for use in the first-line setting for patients with HER2-positive metastatic breast cancer (mBC). OBJECTIVE: This retrospective study investigated the clinical and demographic characteristics, treatment patterns, safety, and clinical outcomes for patients with HER2-positive mBC who received pertuzumab in the first-line setting in US community oncology practices...
March 2017: Drugs—Real World Outcomes
(no author information available yet)
No abstract text is available yet for this article.
August 2016: Anesthesiology
(no author information available yet)
No abstract text is available yet for this article.
December 2015: Anesthesiology
Neelima Denduluri, Debra A Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M Favret, Phuong Khanh Morrow, Richard L Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, Gary H Lyman
BACKGROUND: A wide variety of myelosuppressive chemotherapy regimens are used for the treatment of cancer in clinical practice. Neutropenic complications, such as febrile neutropenia, are among the most common side effects of chemotherapy, and they often necessitate delays or reductions in doses of myelosuppressive agents. Reduced relative dose intensity (RDI) may lead to poorer disease-free and overall survival. METHODS: Using the McKesson Specialty Health/US Oncology iKnowMed electronic health record database, we retrospectively identified the first course of adjuvant or neoadjuvant chemotherapy received by patients without metastases who initiated treatment between January 1, 2007, and March 31, 2011...
November 2015: Journal of the National Comprehensive Cancer Network: JNCCN
Nicholas J Di Bella, Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Zachary Cain, Tony Okoro, Bjorn Bolinder, Debra Patt, Elias J Jabbour
BACKGROUND: Clinical outcomes of patients with chronic myeloid leukemia (CML) treated in clinical trials, including response to therapy, may not be representative of those treated in a community setting. Thus, we sought to determine the real-world effectiveness of first-line tyrosine kinase inhibitors in CML by evaluating response rates, all-cause discontinuation, and adherence. Response monitoring patterns were also analyzed. PATIENTS AND METHODS: This retrospective observational study, using the McKesson Specialty Health/US Oncology Network (MSH/USON) iKnowMed electronic health record database and medical charts, identified newly diagnosed CML patients who received first-line imatinib, dasatinib, or nilotinib from July 2007 to March 2011, and were then followed for ≥ 18 months...
October 2015: Clinical Lymphoma, Myeloma & Leukemia
Marcus A Neubauer, Cynthia B Taniguchi, J Russell Hoverman
Documentation of a patient's preferred code status is a critical outcome of advance care planning. Although there is agreement that code status is valuable information, little progress has been made to increase the incidence of documented code status within the medical record in an outpatient setting. Incidence of code status documentation in the community oncology setting has not been studied. In April 2013, the US Oncology Network and McKesson Specialty Health launched a new advance care planning initiative for the purpose of promoting conversations between clinicians and patients regarding end-of-life care preferences...
March 2015: Journal of Oncology Practice
Clara Chen, Arliene Ravelo, Elaine Yu, Rahul Dhanda, Ian Schnadig
This analysis evaluated the efficacy and safety of bevacizumab as monotherapy and with irinotecan for recurrent glioblastoma in community-based practices. Adult patients with bevacizumab-naive, recurrent glioblastoma initiating second-line treatment (July 2006-June 2010) were identified using McKesson Specialty Health/US Oncology Network health records. Overall (OS) and progression-free survival (PFS) estimates were analyzed through July 2011 and compared for bevacizumab and non-bevacizumab regimens using the log-rank test...
May 2015: Journal of Neuro-oncology
Laura Putre
No abstract text is available yet for this article.
August 2014: Hospitals & Health Networks
Ian D Schnadig, Thomas E Hutson, Hsingwen Chung, Rahul Dhanda, Melissa Halm, Michael Forsyth, Nicholas J Vogelzang
BACKGROUND: This retrospective study by McKesson Specialty Health (MSH)/US Oncology Network (USON) evaluates dosing patterns of first-line sunitinib for patients with advanced renal cell carcinoma (aRCC) and its association with toxicities and clinical outcomes in community practices. PATIENTS AND METHODS: Patients with aRCC who started first-line sunitinib between June 1, 2007, and May 31, 2011, were identified from 17 MSH/USON practices. Clinical data were extracted from iKnowMed electronic medical records linked to the MSH/USON pharmacy database...
December 2014: Clinical Genitourinary Cancer
Ronald L Dunn
This article demonstrates how enterprise intelligence systems can be used to improve operational efficiency in hospitals. Enterprise intelligence systems mine raw data from disparate systems and transform the data into actionable information, which when used appropriately, support streamlined processes, optimize resources, and positively affect staff efficiency and the quality of patient care. Case studies on the implementation of McKesson Performance Visibility and Capacity Planner enterprise intelligence solutions at the Southlake Regional Health Centre and Lions Gate and Richmond Hospitals are provided...
2014: Healthcare Management Forum
J Russell Hoverman, Ira Klein, Debra W Harrison, Jad E Hayes, Jody S Garey, Robyn Harrell, Maria Sipala, Scott Houldin, Melissa D Jameson, Mitra Abdullahpour, Jessica McQueen, Greg Nelson, Diana K Verrilli, Marcus Neubauer
PURPOSE: The Innovent Oncology Program aims to improve the value of cancer care delivered to patients. McKesson Specialty Health and Texas Oncology (TXO) collaborated with Aetna to launch a pilot program. The study objectives were to evaluate the impact of Innovent on Level I Pathway compliance, implement the Patient Support Services program, and measure the rate and costs associated with chemotherapy-related emergency room (ER) visits and hospital admissions. PATIENTS AND METHODS: This was a prospective, nonrandomized evaluation of patients enrolled in Innovent from June 1, 2010, through May 31, 2012...
January 2014: Journal of Oncology Practice
Ifat Lavi, Guy Malki, Ran Kornowski
The present study aims to describe a dedicated cardiac imaging application on a tablet and to assess the accuracy and reproducibility of this novel application for measurement on angiography and echocardiography data sets. Tablet devices have recently been used in radiological image interpretation and enable transfer of images. It allows the clinician to look up clinical information, search the Internet and communicate with colleagues and family. The study group consisted of 30 patients who had both echocardiographic and angiographic examinations...
February 2014: International Journal of Cardiovascular Imaging
Hao Wang, Richard D Robinson, Marco Coppola, David Fernandez, Ferran Ros, Nestor R Zenarosa, Mandy J Burton, Kathleen A Delaney
McKesson's Interqual criteria are one of the medical screening criteria that are widely used in emergency departments (EDs) to determine if patients qualify for observation or inpatient admission. Chronic heart failure (CHF) is one of the most common yet severe cardiovascular diseases seen in the ED with a relatively higher admission rate. This study is to evaluate the accuracy of Interqual criteria in determining observation versus hospitalization need in CHF patients. From January 2009 till December 2010, data from 503 CHF patients were reviewed...
December 2013: Critical Pathways in Cardiology
M Racy, S Al-Nammari, C B Hing
Trauma registries are used worldwide to coordinate patient care as well as provide data for audit and research purposes. National registries collect this data, producing research opportunities, outcome standards and a means by which to benchmark trauma centre performance. The Trauma Audit and Research Network (TARN) is the UK national registry, with data upload being mandatory from all major trauma centres (MTCs), a process which is manual and time and resource intensive. A telephone survey was carried out to collect data from all 26 MTCs in England...
March 2014: Injury
Paul Barr
No abstract text is available yet for this article.
August 2013: Hospitals & Health Networks
Clara Chen, Rahul Dhanda, Wan-Yu Tseng, Michael Forsyth, Debra A Patt
PURPOSE: Oncotype Dx 21-gene assay recurrence score (RS) predicts recurrence of early-stage breast cancer (ESBC). We investigated whether patient, tumor, or practice characteristics drive its use and explored Oncotype DX RS and chemotherapy use in subgroups. METHODS: Patients with ESBC with documented estrogen receptor-positive, lymph node-negative, human epidermal growth factor receptor 2-negative tumors registered within McKesson Specialty Health's iKnowMed electronic health record were included...
July 2013: Journal of Oncology Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"